Home
About Us
Our Technology
Our Pipeline
Patients
Investors & Media
Career
Contact Us
EN—CN

I can feel my health improving, not just mentally, I can now even do house
chores like I used to. With every follow up visit, the data proves my recovery.
For someone with fairly advanced stage cancer, I never dreamed CAR-T would
bring such results. Now I'm enjoying every day I'm spending with my family.
“

Mr. Hu
Hepatocellular Carcinoma BCLC Staging B
Received CAR-T therapy on September 25, 2020

I can feel my health improving, not just mentally,
I can now even do house chores like I used to.
With every follow up visit, the data proves my
recovery. For someone with fair advanced stage
cancer, I never dreamed CAR-T would bring
such results. Now I'm enjoying every day I'm
spending with my family.
“

Mr. Hu
Hepatocellular Carcinoma BCLC Staging B
Received CAR-T therapy on September 25, 2020

When the doctor said "You have recovered" in the phone, I was shocked.
This is the first time I've heard anything like that after years and countless
treatments since I've been diagnosed with liver cancer. CAR-T therapy
gave me the will to live!
“

Mrs. Fang
Hepatocellular Carcinoma BCLC Staging C
Received CAR-T therapy on January 25, 2021

When the doctor said "You have recovered"
in the phone, I was shocked. This is the first
time I've heard anything like that after years
and countless treatments since I've been
diagnosed with liver cancer. CAR-T therapy
gave me the will to live!
“

Mrs. Fang
Hepatocellular Carcinoma BCLC Staging C
Received CAR-T therapy on January 25, 2021

We are a clinical-stage biotech company focusing on innovating effective and affordable cell therapies for the global patient community.
We strive to become a leader in immunotherapy, leveraging our strong scientific foundation and our ability to generate competitive proof-of-concept data by collaborating with top investigators.
Our goal is to find cure for patients through the development of next-generation cell therapies and to ultimately return life quality to patients and their families.

Return to health, Restart vitality

Founded in 2015, Oricell Therapeutics is dedicated to pioneering innovative and clinically valuable immunotherapies focusing on a wide range of indications. Committed to cost-effective and enduring cellular drugs, we strive to address global clinical needs, aiming to profoundly impact patients' lives and help them "return to health, restart vitality" through our advancements in life sciences.

  • Our Mission

    Dedicated to developing effective and accessible immunotherapeutics
    and extend the life of cancer patients.

    Dedicated to developing effective
    and accessible immunotherapeutics
    and extend the life of cancer patients.

  • Our Vision

    To become a global leader in innovation-drive
    novel immunotherapies.

  • Our Values

    Patient-first, Scientific Excellence,
    Integrity, Synergy and Collaboration

Core Team

Helen Yang, Ph.D.

Co-founder/Chairperson/CEO

Helen Yang, Ph.D.

Co-founder/Chairperson/CEO

Helen is a successful business leader with 3 decades of operations and management experience. She has a remarkable track record, having served as a C-suite manager for two publicly listed companies and one private company across various industries.
Helen received her EMBA at CEIBS and Ph.D. at Tongji University in China.

Peter He, Ph.D.

Co-founder & CSO

Peter He, Ph.D.

Co-founder & CSO

Peter is a highly accomplished molecular biologist and immunologist, boasting over 20 years of extensive expertise in the field. He remains unwavering in his dedication to advancing the scientific domain through pioneering research in cell development and metabolism, with a specific emphasis on tumor immune microenvironment. Notably, he prioritizes innovation and has effectively guided his team in creating a cutting-edge technology platform for Oricell.
Peter completed his post-doctoral training at University of Medicine and Dentistry of New Jersey.

Rick Xu, Ph.D.

Chief Medical Officer

Rick Xu, Ph.D.

Chief Medical Officer

With over 30 years of experience in the pharmaceutical industry, Dr. Rick Xu has respectively worked for Sterling Winthrop, Pfizer, Hoffman-La Roche and Genentech, and successfully designed, engineered and developed two multi-billion dollar products, the PEGSYS and the Long Acting Filgrastim. Since 2006, Dr. Xu has been acting as Sr. Director, Expert Scientist of Translational Medicine in Oncology and Clinical Pharmacology, focusing on global clinical drug development of immune oncology therapeutic products. Dr. Xu has served as the president and chairman of SAPA and member of China RDA Drug Clinical Trials Committee.

Iris Huang

Chief Financial Officer & Chief of Staff

Iris Huang

Chief Financial Officer & Chief of Staff

Iris is an ex-life science investment banker with over 11 years’ experiences in Asia and the U.S. Prior to joining Oricell, Iris served as Executive Director at J.P. Morgan’s global investment banking team and Vice President at Bank of America Merrill Lynch, where her major role was to advise, strategize and execute corporate finance and capital market transactions for leading pharma companies across regions. Iris received her bachelor degree in BBA of Finance and BS of Psychology from Emory University and MSc in Law and Accounting from LSE.





Scientific Advisory Board

Shaji Kumar

M.D

Shaji Kumar

M.D

Dr. Kumar is the Mark and Judy Mullins Professor of Hematologic Malignancies at Mayo Clinic as well as Research Chair, Division of Hematology, Department of Internal Medicine at Mayo. He received his medical degree from All-India Institute of Medical Sciences and completed his residency and fellowship training in internal medicine, medical oncology, and hematology at Mayo and Dana-Farber Harvard Cancer Institute. He is also an active member and leader of various professional societies and committees, such as the American Society of Hematology, the International Myeloma Society, the International Society of Amyloidosis, and the National Comprehensive Cancer Network.

Kenneth C. Anderson

M.D.

Kenneth C. Anderson

M.D.

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute.

History

2024

  • · ·Prof. Ken Anderson and Prof. Shaji Kumar joined the Scientific Advisory Board.
  • · ·Established in‑house OnGo Rapid Process CMC Platform, significantly reducing production cycle time and cost.
  • · ·Established in‑house lentiviral vector (LVV) development platform with high titer, yield, and scalability.
  • · ·Invited to deliver an oral presentation at the 42nd J.P. Morgan Healthcare Conference.

2023

  • · ·Named one of the Top‑10 Most Notable Cell Therapy Companies globally.
  • · ·Listed among 2023 China Potential Unicorn Enterprises.
  • · ·Awarded “Future Star – Top 100 Rising Companies” by China Entrepreneur Magazine.
  • · ·Won the Gold Award at the Shanghai Haiju Talents Global Innovation & Entrepreneurship Competition.

2022

  • · NovemberOricell and Cytiva Signs Strategic Cooperation Agreement at the 5th China International Import Expo
  • · OctoberGPRC5D CAR-T receives Orphan Drug Designation from FDA
  • · SeptemberReceives Implied License from NMPA for Ori-C101 IND Application
  • · AugustRaises Over $120 Million in Series B Financing

2021

  • · DecemberOricell Therapeutics once again receives "High and New Technology Enterprise" recognition since November 2018
  • · NovemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting

2020

  • · DecemberReceived the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets<br>Established the Shanghai Academician (Expert) Workstation<
  • · NovemberEstablished the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
  • · OctoberWon the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition
  • · JuneResponsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality<br>Reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD

2024

  • · ·OriCAR‑017: Long‑term follow‑up data selected for an oral presentation at ASCO 2024.
  • · ·OriCAR‑017: Received FDA Fast Track designation.
  • · ·OriC613: Obtained NMPA IND approval.
  • · ·OriC322: Preclinical data selected for an oral presentation at STIC 2024 and poster presentation at ASH 2024.

2023

  • · ·Closed $45M Series B1 financing.
  • · ·Ori C101: Dosed the first patient in the Phase I trial.
  • · ·OriCAR 017: Long term follow up data from the IIT accepted for publication in The Lancet Haematology.
  • · ·OriCAR 017: Completed China–US technology transfer within six months and submitted an IND to the FDA.
  • · ·Preclinical data for four programs (including OriCAR‑017) accepted for poster presentation at SITC 2023.

2022

  • · JuneReports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
  • · MayOriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress<br>Selected in Shanghai Professional, Refined, Specialized, Novel Businesses List
  • · AprilCAR-T product candidate OriCAR-017 clinical data abstract selected for oral presentation at ASCO 2022

2021

  • · AugustOricell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
  • · JuneThe first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO
  • · MayOricell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."

2019

  • · DecemberReceived the pre-A round of exclusive funding from Qiming Venture Partners

2024

  • · ·Prof. Ken Anderson and Prof. Shaji Kumar joined the Scientific Advisory Board.
  • · ·Established in‑house OnGo Rapid Process CMC Platform, significantly reducing production cycle time and cost.
  • · ·Established in‑house lentiviral vector (LVV) development platform with high titer, yield, and scalability.
  • · ·Invited to deliver an oral presentation at the 42nd J.P. Morgan Healthcare Conference.

2024

  • · ·OriCAR‑017: Long‑term follow‑up data selected for an oral presentation at ASCO 2024.
  • · ·OriCAR‑017: Received FDA Fast Track designation.
  • · ·OriC613: Obtained NMPA IND approval.
  • · ·OriC322: Preclinical data selected for an oral presentation at STIC 2024 and poster presentation at ASH 2024.

2023

  • · ·Named one of the Top‑10 Most Notable Cell Therapy Companies globally.
  • · ·Listed among 2023 China Potential Unicorn Enterprises.
  • · ·Awarded “Future Star – Top 100 Rising Companies” by China Entrepreneur Magazine.
  • · ·Won the Gold Award at the Shanghai Haiju Talents Global Innovation & Entrepreneurship Competition.

2023

  • · ·Closed $45M Series B1 financing.
  • · ·Ori C101: Dosed the first patient in the Phase I trial.
  • · ·OriCAR 017: Long term follow up data from the IIT accepted for publication in The Lancet Haematology.
  • · ·OriCAR 017: Completed China–US technology transfer within six months and submitted an IND to the FDA.
  • · ·Preclinical data for four programs (including OriCAR‑017) accepted for poster presentation at SITC 2023.

2022

  • · NovemberOricell and Cytiva Signs Strategic Cooperation Agreement at the 5th China International Import Expo
  • · OctoberGPRC5D CAR-T receives Orphan Drug Designation from FDA
  • · SeptemberReceives Implied License from NMPA for Ori-C101 IND Application
  • · AugustRaises Over $120 Million in Series B Financing

2022

  • · JuneReports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
  • · MayOriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress<br>Selected in Shanghai Professional, Refined, Specialized, Novel Businesses List
  • · AprilCAR-T product candidate OriCAR-017 clinical data abstract selected for oral presentation at ASCO 2022

2021

  • · DecemberOricell Therapeutics once again receives "High and New Technology Enterprise" recognition since November 2018
  • · NovemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting

2021

  • · AugustOricell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
  • · JuneThe first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO
  • · MayOricell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."

2020

  • · DecemberReceived the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets<br>Established the Shanghai Academician (Expert) Workstation<
  • · NovemberEstablished the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
  • · OctoberWon the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition
  • · JuneResponsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality<br>Reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD

2019

  • · DecemberReceived the pre-A round of exclusive funding from Qiming Venture Partners
More

Proprietary and Innovative Technology Platforms

Proprietary, unique, adaptive CAR-T platform
Focusing on developing first-in-class and best-in-class immunotherapies

More

Diverse Pipeline

More than 10 CAR-T product pipelines
4 in clinical validation stage with 2 in registered phase I clinical trial

More
Thinkart

Helen Yang, EMBA

Co-founder/Chairperson/CEO

Helen is a successful business leader with 3 decades of operations and management experience. She has a remarkable track record, having served as a C-suite manager for two publicly listed companies and one private company across various industries. Additionally, Helen co-founded and successfully led the IPO of Canature (300272).
Helen received her Bachelor degree at Beijing Institute of Technology, EMBA at CEIBS and is a Ph.D. candidate at Tongji University in China.

Peter He, Ph.D.

Co-founder & CSO

Peter is a highly accomplished molecular biologist and immunologist, boasting over 20 years of extensive expertise in the field. He remains unwavering in his dedication to advancing the scientific domain through pioneering research in cell development and metabolism, with a specific emphasis on tumor immune microenvironment. Notably, he prioritizes innovation and has effectively guided his team in creating a cutting-edge technology platform for Oricell.
Peter received a doctoral degree in molecular biology and genetics at Second Military Medical University in China and completed his post-doctoral training at University of Medicine and Dentistry of New Jersey.

Weidong Cui, Ph.D.

CTO, GM Oricell (US)

Dr. Cui brings over 25 years of CMC experience. Prior to joining Oricell, Dr. Cui served as the CTO of Fosun Kite, led the tech transfer, NDA submission and commercial launch of the first autologus CAR-T therapy Yescarta® (Axi-Cel) in China. Before Fosun Kite, Dr. Cui also served in various senior management and scientific roles in MedImmune and AstraZeneca.
Dr. Cui received his Ph.D. at SUNY ESF Syracuse University and completed his post-doctoral training at UCSF.